Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
CLA3884 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A50034 | 35555962 | Intern Med J | The short-term outcomes of patients with chronic liver disease hospitalized with COVID-19. | 2022 | Details |
| A50038 | 35551103 | Gut Liver | Waiting for Multi-Stakeholders'Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature. | 2022 | Details |
| A50050 | 35545903 | Environ Sci Technol | Lipid Metabolic Disorder Induced by Pyrethroids in Nonalcoholic Fatty Liver Disease of Xenopus laevis. | 2022 | Details |
| A50053 | 35545437 | Clin Mol Hepatol | NAFLD versus MAFLD: Prevalence, Outcomes and Implications of a Change in Name. | 2022 | Details |
| A50058 | 35542976 | Ann Palliat Med | A clinical and laboratory-based nomogram for predicting nonalcoholic fatty liver disease in non-diabetic adults: a cross-sectional study. | 2022 | Details |
| A50063 | 35538056 | Nat Commun | A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A50065 | 35537665 | Magn Reson Imaging | Comparison of automatic liver volumetry performance using different types of magnetic resonance images. | 2022 | Details |
| A50071 | 35535099 | J Clin Exp Hepatol | Prevalence of Risk Factors for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Patients With Cryptogenic Cirrhosis. | 2021 | Details |
| A50076 | 35535068 | J Clin Exp Hepatol | FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort. | 2021 | Details |
| A50079 | 35535063 | J Clin Exp Hepatol | Gallstone Disease in Cirrhosis-Pathogenesis and Management. | 2021 | Details |
| A50080 | 35534573 | Nat Rev Endocrinol | Macrophage functional diversity in NAFLD - more than inflammation. | 2022 | Details |
| A50081 | 35534202 | J Clin Pathol | Postmortem survey of haemoglobin A1c, non-alcoholic steatohepatitis and liver fibrosis within a general population. | 2022 | Details |
| A50092 | 35531334 | Front Cell Infect Microbiol | Yiqi-Bushen-Tiaozhi Recipe Attenuated High-Fat and High-Fructose Diet Induced Nonalcoholic Steatohepatitis in Mice via Gut Microbiota. | 2022 | Details |
| A50101 | 35528835 | Front Cardiovasc Med | Salvia miltiorrhiza Bge. (Danshen) in the Treating Non-alcoholic Fatty Liver Disease Based on the Regulator of Metabolic Targets. | 2022 | Details |
| A50109 | 35523460 | BMJ Open Gastroenterol | Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease. | 2022 | Details |
| A50111 | 35521691 | Bioengineered | The macrophage-associated microRNA-4715-3p / Gasdermin D axis potentially indicates fibrosis progression in nonalcoholic fatty liver disease: evidence from transcriptome and biological data. | 2022 | Details |
| A50119 | 35514152 | Hepatology | NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status. | 2022 | Details |
| A50134 | 35508191 | Am J Physiol Cell Physiol | The role of mitochondria in the pathophysiology and treatment of common metabolic diseases in humans. | 2022 | Details |
| A50144 | 35503803 | Hepatol Commun | Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex. | 2022 | Details |
| A50157 | 35500802 | J Ethnopharmacol | Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice. | 2022 | Details |
| A50167 | 35493764 | JHEP Rep | Deprescribing zolpidem reduces falls and fractures in patients with cirrhosis. | 2022 | Details |
| A50187 | 35485207 | Hepatol Commun | A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis. | 2022 | Details |
| A50194 | 35483603 | Clin Gastroenterol Hepatol | Discrepancy Between NAFLD and MAFLD: Is it Only Due to Misclassification of MAFLD? | 2022 | Details |
| A50195 | 35483092 | J Comput Assist Tomogr | Diagnostic Feasibility of Magnetic Resonance Elastography Radiomics Analysis for the Assessment of Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50203 | 35477031 | Ann Hepatol | Non-invasive methods for iron overload evaluation in dysmetabolic patients. | 2022 | Details |
| A50219 | 35468693 | Front Biosci (Landmark Ed) | Quarter-Century Explorations of Bioactive Polyphenols: Diverse Health Benefits. | 2022 | Details |
| A50224 | 35465315 | Front Cell Dev Biol | Multi-Omics Characterizes the Effects and Mechanisms of CD1d in Nonalcoholic Fatty Liver Disease Development. | 2022 | Details |
| A50237 | 35462485 | Zhonghua Gan Zang Bing Za Zhi | [Applied research of ultrasound attenuation parameter in the diagnosis of metabolic dysfunction-associated fatty liver disease]. | 2022 | Details |
| A50278 | 35444985 | Front Public Health | A Machine Learning Based Framework to Identify and Classify Non-alcoholic Fatty Liver Disease in a Large-Scale Population. | 2022 | Details |
| A50285 | 35443488 | J Assoc Physicians India | Comparison of Novel Fibrosis Index (NFI) with Aspartate aminotransferase to platelet ratio index (APRI) in Type II Diabetes mellitus patients with Non alcoholic fatty liver disease and fibrosis (NAFLD). | 2022 | Details |
| A50299 | 35439472 | Chem Biol Interact | Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4/TGF-β1 axis. | 2022 | Details |
| A50306 | 35437549 | Food Funct | L-Methionine supplementation attenuates high-fat fructose diet-induced non-alcoholic steatohepatitis by modulating lipid metabolism, fibrosis, and inflammation in rats. | 2022 | Details |
| A50316 | 35434927 | J Hepatobiliary Pancreat Sci | The impact of pylorus preservation on the development of nonalcoholic fatty liver disease after pancreaticoduodenectomy: A historical cohort study. | 2022 | Details |
| A50317 | 35434888 | Diabetes Obes Metab | Positive allosteric γ-aminobutyric acid type A receptor modulation prevents lipotoxicity-induced injury in hepatocytes in vitro. | 2022 | Details |
| A50318 | 35434848 | J Gastroenterol Hepatol | Association of thyroid autoimmunity with nonalcoholic fatty liver disease in euthyroid middle-aged subjects: A population-based study. | 2022 | Details |
| A50323 | 35433771 | Front Med (Lausanne) | Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma. | 2022 | Details |
| A50334 | 35430025 | J Clin Lipidol | JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. | 2022 | Details |
| A50348 | 35421921 | BMC Microbiol | Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus. | 2022 | Details |
| A50358 | 35419401 | Front Nutr | Empirically-Derived Dietary Patterns in Relation to Non-Alcoholic Fatty Liver Diseases Among Adult Participants in Amol, Northern Iran: A Structural Equation Modeling Approach. | 2022 | Details |
| A50362 | 35417873 | Georgian Med News | HISTOLOGICAL AND HISTOCHEMICAL FEATURES OF LIVER AND LUNG TISSUE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND OBESITY DEPENDING ON THE PRESENCE OF COMORBID CHRONIC OBSTRUCTIVE PULMONARY DISEASE. | 2022 | Details |
| A50363 | 35417465 | PLoS One | The regulation of HBP1, SIRT1, and SREBP-1c genes and the related microRNAs in non-alcoholic fatty liver rats: The association with the folic acid anti-steatosis. | 2022 | Details |
| A50384 | 35409319 | Int J Mol Sci | Hepatic PTEN Signaling Regulates Systemic Metabolic Homeostasis through Hepatokines-Mediated Liver-to-Peripheral Organs Crosstalk. | 2022 | Details |
| A50392 | 35406736 | Cells | Multi-Omics Approach Reveals Dysregulation of Protein Phosphorylation Correlated with Lipid Metabolism in Mouse Non-Alcoholic Fatty Liver. | 2022 | Details |
| A50396 | 35405948 | Nutrients | Do MAFLD Patients with Harmful Alcohol Consumption Have a Different Dietary Intake? | 2022 | Details |
| A50406 | 35402723 | Clin Exp Hepatol | Correlation of liver-to-spleen ratio on computed tomography with colorectal polyps. | 2021 | Details |
| A50417 | 35399069 | BMC Endocr Disord | Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials. | 2022 | Details |
| A50427 | 35396116 | Endocrinol Diabetes Nutr (Engl Ed) | Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity. | 2022 | Details |
| A50460 | 35382785 | BMC Public Health | Effect of physical activity on the development and the resolution of nonalcoholic fatty liver in relation to body mass index. | 2022 | Details |
| A50498 | 35364328 | Endocr Pract | Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals. | 2022 | Details |
| A50503 | 35360107 | Front Cell Infect Microbiol | Porphyromonas gingivalis Induces Increases in Branched-Chain Amino Acid Levels and Exacerbates Liver Injury Through livh/livk. | 2022 | Details |
| A50521 | 35354697 | Endocr J | Increased brain-derived neurotrophic factor in the serum of persons with nonalcoholic fatty liver disease. | 2022 | Details |
| A50522 | 35354641 | BMJ Health Care Inform | Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH). | 2022 | Details |
| A50523 | 35354619 | BMJ Open | Validation of type 2 diabetes subgroups by simple clinical parameters: a retrospective cohort study of NHANES data from 1999 to 2014. | 2022 | Details |
| A50524 | 35354614 | BMJ Open | Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. | 2022 | Details |
| A50567 | 35338446 | Diabetes Ther | Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications. | 2022 | Details |
| A50585 | 35332569 | Hepatology | Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. | 2022 | Details |
| A50596 | 35328955 | Int J Environ Res Public Health | Risk of Nonalcoholic Fatty Liver Disease Is Associated with Urinary Phthalate Metabolites Levels in Adults with Subclinical Hypothyroidism: Korean National Environmental Health Survey (KoNEHS) 2012-2014. | 2022 | Details |
| A50647 | 35317172 | World J Hepatol | Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations? | 2022 | Details |
| A50653 | 35313531 | Metabol Open | Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents. | 2022 | Details |
| A50682 | 35304191 | Mol Cell Endocrinol | Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism. | 2022 | Details |
| A50685 | 35302279 | Cancer Rep (Hoboken) | Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy. | 2022 | Details |
| A50693 | 35299291 | Clin Mol Hepatol | Association of Nonalcoholic Fatty Liver Disease with Incident Dementia Later in Life Among Elder Adults. | 2022 | Details |
| A50698 | 35296223 | Nutr Neurosci | RNA-sequencing revealed apple pomace ameliorates expression of genes in the hypothalamus associated with neurodegeneration in female rats fed a Western diet during adolescence to adulthood. | 2022 | Details |
| A50700 | 35295576 | Front Physiol | Polyene Phosphatidylcholine Ameliorates High Fat Diet-Induced Non-alcoholic Fatty Liver Disease via Remodeling Metabolism and Inflammation. | 2022 | Details |
| A50724 | 35286799 | Clin Mol Hepatol | Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: a narrative review. | 2022 | Details |
| A50728 | 35285529 | Aliment Pharmacol Ther | Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. | 2022 | Details |
| A50731 | 35284290 | Quant Imaging Med Surg | Diagnosis of steatohepatitis and fibrosis in biopsy-proven nonalcoholic fatty liver diseases: including two-dimension real-time shear wave elastography and noninvasive fibrotic biomarker scores. | 2022 | Details |
| A50732 | 35284276 | Quant Imaging Med Surg | Ultrasonographic index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. | 2022 | Details |
| A50749 | 35278680 | Ann Hepatol | Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. | 2022 | Details |
| A50750 | 35278405 | Eur J Pharmacol | Inonotus obliquus and its bioactive compounds alleviate non-alcoholic fatty liver disease via regulating FXR/SHP/SREBP-1c axis. | 2022 | Details |
| A50785 | 35268076 | Nutrients | The Effect of Dietary Interventions on Hypertriglyceridemia: From Public Health to Molecular Nutrition Evidence. | 2022 | Details |
| A50807 | 35234696 | Chin Med J (Engl) | Therapeutic developments in metabolic dysfunction-associated fatty liver disease. | 2022 | Details |
| A50870 | 34728983 | J Clin Exp Hepatol | Predictors of in-hospital Outcomes in Patients With Cirrhosis and Coronavirus Disease-2019. | 2021 | Details |
| A50876 | 34662702 | Magn Reson Imaging | Free-breathing 3D stack-of-radial MRI quantification of liver fat and R2* in adults with fatty liver disease. | 2021 | Details |
| A50892 | 34224877 | Clin Gastroenterol Hepatol | Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease. | 2021 | Details |
| A50895 | 34153396 | J Hepatol | Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality? | 2021 | Details |
| A51031 | 23376892 | J Hepatol | Regular coffee: a magic bullet or a naked gun? Regular coffee but not espresso drinking is protective against fibrosis in NAFLD. | 2013 | Details |
| A51032 | 23376891 | J Hepatol | Reply to: "regular coffee: a magic bullet or a naked gun? Regular coffee but not espresso drinking is protective against fibrosis in NAFLD". | 2013 | Details |
| A51088 | 35819939 | Chem Res Toxicol | Automating Predictive Toxicology Using ComptoxAI. | 2022 | Details |
| A51094 | 35783472 | Hepatol Forum | A single-center experience: Liver biopsy results during a year. | 2022 | Details |
| A51099 | 35778902 | J Ultrasound Med | Interobserver Variability in Ultrasound-Based Liver Fat Quantification. | 2022 | Details |
| A51101 | 35765803 | Ultrasonography | Accuracy of attenuation imaging in the assessment of pediatric hepatic steatosis: correlation with the controlled attenuation parameter. | 2022 | Details |
| A51106 | 35736002 | mSystems | Identification and Characterization of Major Bile Acid 7α-Dehydroxylating Bacteria in the Human Gut. | 2022 | Details |
| A51116 | 35678690 | Curr Issues Mol Biol | The Protective Role of 4-Acetylarylquinolinol B in Different Pathological Processes. | 2022 | Details |
| A51117 | 35677505 | J Clin Exp Hepatol | Application of Noninvasive Tools to Decide the Need for Beta-Blockers for Variceal Bleeding Prophylaxis in Compensated Advanced Liver Disease: A Decision Curve Analysis. | 2021 | Details |
| A51143 | 35504562 | Clin Gastroenterol Hepatol | Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy. | 2022 | Details |
| A51144 | 35502211 | Oxid Med Cell Longev | Research Progress of Ferroptosis in Adiposity-Based Chronic Disease (ABCD). | 2022 | Details |
| A51183 | 35317824 | Diabetol Metab Syndr | Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease. | 2022 | Details |
| A51245 | 35761115 | Arch Pharm Res | Alcoholic liver disease: a new insight into the pathogenesis of liver disease. | 2022 | Details |
| A51247 | 35501284 | Diagn Interv Imaging | Liver spontaneous hypoattenuation on CT is an imaging biomarker of the severity of acute pancreatitis. | 2022 | Details |
| A51250 | 35318125 | Biochim Biophys Acta Mol Basis Dis | Kupffer cells are protective in alcoholic steatosis. | 2022 | Details |
| A51283 | 468098 | Hokkaido Igaku Zasshi | [Chronic hepatitis--clinicopathological studies of 687 cases (author's transl)]. | 1979 | Details |
| A51302 | 35781089 | Ann Hepatol | Liver resection for single large hepatocellular carcinoma: a prognostic factors study. | 2022 | Details |
| A51311 | 35702843 | J Assoc Physicians India | Spontaneous Ascitic Fluid Infection: Are we Experiencing an Epidemiological shift in Causative Organisms? | 2022 | Details |
| A51317 | 35674880 | Clin Pharmacokinet | Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. | 2022 | Details |
| A51319 | 35644437 | J Ethnopharmacol | Uncovering the mechanism of Huanglian-Wuzhuyu herb pair in treating nonalcoholic steatohepatitis based on network pharmacology and experimental validation. | 2022 | Details |
| A51322 | 35625520 | Biology (Basel) | PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH). | 2022 | Details |
| A51361 | 35294954 | PLoS One | Cardiovascular disease risk in liver transplant recipients transplanted due to chronic viral hepatitis. | 2022 | Details |
| A51373 | 33311893 | J Clin Exp Hepatol | Early Hepatocellular Carcinoma Treated by Radiofrequency Ablation-Mid- and Long-Term Outcomes. | 2020 | Details |
| A51399 | 35814505 | J Clin Exp Hepatol | Surgical Risk Assessment in Patients with Chronic Liver Diseases. | 2022 | Details |